Skip to main content
Log in

Fasoracetam

LAM 105, NS 105

  • Section 2: Dementia Syndrome in Japan
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Oka M, Fukui T, Itoh Y, et al. NS-105 a novel nootropic agent, reverses GABA(B) receptor-mediated inhibition of cyclic AMP accumulation in the rat brain. J Neurochem 1995; 65 Suppl.: 164

    Google Scholar 

  2. Graul A, Tracy M, Castañer J. NS-105. Drugs Future 1997 Jun; 22: 639–40

    CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fasoracetam. Drugs R&D 2, 135–136 (1999). https://doi.org/10.2165/00126839-199902020-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902020-00014

Keywords

Navigation